| 儿童矮小症应用生长激素的长期安全性 |
| |
| 引用本文： | 张晓洁.儿童矮小症应用生长激素的长期安全性[J].临床儿科杂志,2011,29(8). |
| |
| 作者姓名： | 张晓洁 |
| |
| 作者单位： | 上海交通大学医学院附属上海儿童医学中心,上海,200127 |
| |
| 摘 要： | 生长激素(GH)于1956年首先从人垂体中分离出,其生物化学结构直到1972年才阐明.重组DNA技术和基因工程方法,实现了人生长激素(hGH)的大规模生产,使hGH普遍利用成为可能.文章综述生长激素在儿童生长激素缺乏症、慢性肾功能不全、Turner综合征、Prader-Willi综合征、小于胎龄儿持续矮小、特发性矮小、矮小同源异型盒基因(SHOX)缺陷疾病中的应用方法和安全性.提示重组hGH用于儿童的安全性令人满意,但也需注意有潜在风险的特殊群体.
|
| 关 键 词： | 生长激素 矮小症 安全性 |
Long-term safety of recombinant human growth hormone treatment in children |
| |
| ZHANG Xiao-jie.Long-term safety of recombinant human growth hormone treatment in children[J].The Journal of Clinical Pediatrics,2011,29(8). |
| |
| Authors: | ZHANG Xiao-jie |
| |
| Institution: | ZHANG Xiao-jie,SHEN Yong-nian(Shanghai Children's Medical Center,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China) |
| |
| Abstract: | Growth hormone(GH)was isolated firstly from the human pituitary gland in 1956,but its biochemical structure was not elucidated until 1972.The first recombinant human GH(rhGH)was developed by a process called recombinant DNA technology.This is currently the most common method used to synthesize rhGH,which lead to full scale operation coming true.Long-term safety of using rhGH in children with growth hormone deficiency,chronic renal insufficiency,Turner syndrome,Prader-Willi syndrome,small for gestational age... |
| |
| Keywords: | growth hormone short stature safety |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
